List of Biotech, Pharmaceutical & Life Sciences companies in Israel - 140

3NT Medical is taking ENT endoscopy further, with a family of novel maneuverable, single-use endoscopes purpose-built for the unique needs of ENT specialists.

Valuing Life, Granting Advanced Therapies to Patients- that Is Adva Biotechnology’s Vision and goal. Adva Biotechnology developed the ADVA-X3- a simple, smart, easy to use, automated, sensors-based, flexible cell manufacturing platform. The ADVA-X3 enables full manufacturing process based on the CAMP™ technology, of different applications, such as CAR-T, TCR, TIL, NK, Exosomes, Viruses and More.

Aleph Farms®, an Israel-based cellular agriculture company, enhances sustainability, food security and animal welfare by diversifying the supply and decentralizing the production of quality animal proteins and fats as a complement to sustainable methods of conventional animal agriculture. Founded in 2017, the company unveiled the world's first cultivated thin-cut beef steak in 2018, the world's first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts™, the company is launching its first product, the cultivated Petit Steak, grown from non-modified cells of a premium Black Angus cow. For its contributions to climate leadership, including a net zero commitment made in 2020, it has received top accolades from the World Economic Forum and the United Nations.

Alma Therapeutics is developing a novel drug delivery platform for the oral delivery of complex molecules and biologics such as: Peptides, Proteins and Antibodies

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

ART BioScience was founded in December 2015 by Mr. Oren Ozeri and Mr. Alon Hazan, fathers of two children diagnosed with Duchenne. After co-founding the Israeli Duchenne Parent Association and increased involvement in following current research, Alon and Oren swore to do everything possible to save the lives of their children and dedicated their time and resources to trying to find a cure for the disease. The result of their intensive research and involvement in the field led them to the decision to establish ART, a company based on novel messenger RNA (mRNA) technologies for the development of new therapeutics that can potentially change the course of the disease. ​We are developing Dystrophin modified mRNA encapsulated in LNP (Lipid Nanoparticles) proprietary delivery system as: 1.) Protein Replacement Therapy 2.) CRISPR Cas9 mRNA as Gene Editing Therapy

Azura Ophthalmics is utilizing our deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of Ophthalmic Keratolytics to treat underserved ophthalmic conditions. Our differentiated approach combines ophthalmologic and dermatologic solutions to harness the unique properties of keratolytics to treat the root cause of numerous underserved ocular indications. Our internally discovered pipeline of new chemical entities allows us to develop a portfolio of first-in-class ophthalmic therapeutics for significant unmet needs.

BioGenCell was founded with the vision of developing safe, effective, and long-lasting effective treatment for incurable, blood vessel diseases that will be both accessible and patient friendly. Our disruptive TRACT technology platform provides a comprehensive approach for rapid manufacturing and commercialization of cell-therapies.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 16 years and >$75M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a "target optimized" combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Plant Cell Culture Development and Manufacturing: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, cosmeceutical, and nutraceutical partners to develop proprietary botanical formulations with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. 2. Direct to Consumer/Direct to Doctor Nutraceuticals Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has exceeded 50,000 users (>$20M USD Revenue). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to 1,000 grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs. BioHarvest is the only company that produces red grape sourced Piceid resveratrol at an industrial scale

Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine has also developed a suite of unique technologies, MigHit™ – which is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer and ImmunHit™ which is platform technology enables identification of small molecules targeting IFN-g mediated immune response in cancer and inflammation.

BioLight Life Sciences Ltd. is an Israel-based company dedicated to investing in and managing projects focused on eye diseases and ocular treatments. As the only company in Israel specializing exclusively in ophthalmology, BioLight is a leader in this field. It is publicly traded on the Tel Aviv Stock Exchange under the ticker symbol BOLT. The company’s portfolio includes advanced medical devices, medications, diagnostics, and digital medicine aimed at addressing significant needs in ophthalmology. BioLight develops and commercializes products that enhance diagnosis and treatment efficacy for various eye conditions, including glaucoma, dry eye syndrome, and age-related macular degeneration. A notable product is the Eye-D platform, an insertable device designed for the controlled release of ophthalmic medications, which helps improve patient compliance with treatments. BioLight's strategy focuses on expanding its portfolio of ophthalmic technologies, particularly those integrating digital medicine. The company collaborates with a global network of ophthalmic specialists to identify medical needs and assess potential technologies, positioning itself as a key player in the ophthalmology sector both in Israel and internationally.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Biond Biologics is an Israeli clinical-stage biopharmaceutical company Biond is an innovative biotech company developing breakthrough immunotherapies and a pioneering intracellular drug delivery platform for the treatment of cancer patients. Our innovation: Biologics targeting novel immune evasion mechanisms, discovered through in-house research utilizing real-world patient and tumor samples A transformative intracellular delivery platform for biologics, e.g., antibodies or enzymes, inside cells, allowing to drug intracellular targets currently considered "undruggable". Biond Biologics – Novel and innovative immunotherapies for cancer and auto-immune diseases.

Biology is at a tipping point for implementing AI - thanks to rich data, tool availability, compute capacity, and measurable business impact. Our goal is to empower every scientist and biotech firm, making AI-powered insights a natural part of every workflow. From alt-protein foods to new biopharmaceuticals, bioraptor will make it easier, quicker and more cost-effective for scientists to discover, develop and scale processes that get much-needed food and pharma products into the hands of those who need them.

BlueWind Medical is a medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has successfully completed several clinical studies and is focused on bringing this breakthroughRENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market.

BrainsGate is a medical device company committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases. The company's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on two directions: treatment of acute ischemic stroke, and chronic SPG stimulation to treat vascular dementia patients.

For the first time, researchers and companies can accelerate innovation with accessible, accurate, real-time, and reliable Brain Data™ and Brain Insights™.

Bsense Bio Therapeutics is developing small molecules for the treatment of sensory hyperexcitability related disorders. Bsense is pioneering a novel approach targeting multiple hyperexcitability related mechanisms using a single compound, to achieve greater efficacy and safety. Sensory neuron Hyperexcitability refers to a multitude of indications such as Pain, Pruritus, Tinnitus and seizure, in which sensory neurons are excessively active leading to dire clinical and quality of life ramifications for patients. These indications are considered as significant unmet medical needs representing a major healthcare burden. Bsense Bio's approach is based on the targeting of two cation channels, a ligand-gated cation channel and a voltage-gated potassium channel, respectively, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in the modulation of neuronal excitability. The company has generated preclinical proof-of-concept in chronic pain and has recently been generating data in additional hyperexcitability indications in the space of Pruritis and Tinnitus (some of which with Orphan disease designation). The company is financed by Takeda Ventures Inc., OrbiMed Israel Partners, and Johnson & Johnson Innovation (JJDC), RMGP and the Israel Innovation Authority (IIA). Bsense was founded in September 2018 at the FutuRx biotech incubator based on technology that originated from Prof. Bernard Attali and Dr. Asher Peretz work from the Tel Aviv University.

Can-Fite BioPharma Ltd. is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The Company develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. Can-Fite develops its products by harnessing its technology platform which is based on the Gi protein associated A3 adenosine receptor (A3AR).

Can-Fite is an Israel-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of inflammatory, liver, and metabolic diseases.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect precancerous polyps and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. Please view our notice Terms of Use here: https://check-cap.com/terms-of-use/

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.

Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company. Our therapies are designed to address patients' unmet needs through scientifically based integration of drugs with innovative technologies. Clexio's growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson's Disease, Pain and other conditions involving impairment of the neurological system. Patients, and what they are living with, are at the center of everything we do. Our passion is to find ways to help patients regain a sense of balance, health and a life worth living. Clexio's team is comprised of a multi-disciplinary team with vast experience in drug development. We see our team and our partners as the key ingredients to our success. Join our vision to make lives of millions of patients worth living again.

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

Concenter BioPharma - a patented, unique, proven, novel platform of drugs with 3 modes of action. We are advancing a pipeline of products that demonstrate vast potential in addressing multi­billion markets for treating a range of diseases (that require common MoA’s – our Platform). We will become a global specialty biopharmaceutical company focused on people and providing innovative therapies for them. Our Platform will enable us to jump quickly from one product to another without having to rediscover and recreate an underlying technology for each product. we are committed to developing and delivering therapies that work harmoniously with the human body and advance the treatment landscape for people living with life-threatening diseases.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Convergent R.N.R (CRNR) developed a transformational AI driven robotic radiation platform that was exclusively designed to significantly reduce non-therapeutic dose to adjacent critical structures, disrupting a stagnant radiation therapy/surgery equipment market. The uniquely converging low energy x-ray beam fulfils the un-met proton beam therapy promise, for a less toxic (to nearby organs) radiation solution, at a fraction of the cost, while reducing total cost of ownership by eliminating the need for a concrete bunker.

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

DermaDetect is an AI driven software which enables remote diagnosis and treatment of skin disorders. Based on the latest technology, the system helps health care providers grow the efficiency of their workflow, profitability of their clinic while significantly improving patient care. Based on intelligent software, the platform integrates easily with existing systems, is easy to use, accessible 24/7 and has an attractive pay-per usage pricing model.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world's first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

We designed a portable, affordable and easy to use hematology lab, which provides instant results like CBC, complete blood count. The platform technology houses multiple clinical applications and has an AI based microscope. It reduces cost, time and it improves the doctor-patient experience. EFA brings the LAB to the BLOOD and not the BLOOD to the LAB without the need for an expert preparation. EfA is changing the diagnostics paradigm step by step by enabling tests which were ONLY available in the labs/clinics/hospitals etc. to be done ANYTIME and EVERYWHERE. An early and rapid diagnostic is a key to the prevention of overuse and improper medications. Many millions of people cannot access a proper diagnostic due to their medical condition and/or where they live. Bringing as many as possible medical services closer to them, will make a huge impact on how we manage health around the world. The initial application of a complete blood count everywhere will give results in less than 5 minutes ON THE DEVICE. EfA also creates a marketplace for developers, partners and researches adding health-apps for various conditions and future diagnostic needs. EfA's RevDx portable device realtime analysis enables telemedicine applications.

Eitan Medical is reimagining drug delivery with reliable innovation that puts patients at the center of care, making infusion easier and safer than ever before. Patient safety and care is only the starting point, as Eitan Medical goes beyond, delivering connected, intuitive infusion solutions that are designed to improve patients' and clinicians' quality of life across the continuum of care, including hospital, ambulatory care, and home care solutions. For over a decade, Eitan Medical and its global partners have provided safe, intuitive, and flexible infusion solutions that meet evolving drug delivery needs.

We named our company ELGAN Pharma, as we are dedicated to improving outcome for babies who are Extremely Low Gestational Age Newborns (ELGANs). This means they are born more than 3 months before term. ​ Premature birth is the number one cause of newborn deaths. With improved standard-of-care worldwide, survival rate increases, leading to the need of improving outcome and quality of life. ​ ELGAN Pharma is a neonatology-focused biotechnology company, dedicated to developing safe tailored therapies to address medical problems and developmental difficulties that are common in babies born very early.

The NEXUS® Aortic Arch Stent Graft System by Endospan is the only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS® is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS® "Dock and Lock" modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan's NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.

Our mission is to establish new equilibriums – both in patients’ immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body’s native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated.

Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and its pipeline includes five differentiated, first-in-class oral peptide programs, expected to enter the clinic (Phase 1 to Phase 3) by 2025. The Company’s most advanced product candidate, EB613 (oral PTH (1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Enzymit is setting a new paradigm for bioproduction through the design and creation of novel enzymes that streamline production processes, reduce costs and promote sustainability. Through cell-free, synthetic biology bioproduction, we aim to make faster, simpler, and more cost-effective than fermentation-based methods, meeting the demands of a constantly evolving world. Established in 2020 by experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.

Epitomee is a medical devices company developing ingestible devices to tackle some of today's most prevalent chronic diseases at their core with a self-managed, safe and effective way. Epitomee has developed, and is commercializing drug-free self-administered capsules, aimed to prevent diabetes and address overweight & obesity comorbidities by promoting weight loss and establishing a healthier lifestyle.

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

Exero Medical's mission is to empower health care providers with high-quality, actionable post-operative tissue healing data that can save lives, improve prognosis, and reduce cost of care. The company's flagship product, the xBar system, has been granted Breakthrough Device Designation by the FDA.

Eybna is a technology company and a leading terpene manufacturer. Eybna's forward-thinking R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna's strong and profound partnership with academia and leading industry partners, allows the company to constantly integrate advanced research in the process of product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel, and a US office based in California.

Our cutting-edge technology provides medical professionals with real-time monitoring of renal output, a crucial vital sign that aids in the assessment of a patient's hemodynamic status in various clinical settings, including operating rooms and critical care units. By utilizing our solution, healthcare providers detect and address potential complications promptly, reducing hospitalization-related complications and saving lives.

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Our corporate headquarters is located in Tel Aviv, Israel. For more information about Galmed, please visit our website at: www.galmedpharma.com

At Gamida Cell, we are striving to enable patients with blood cancers and serious blood disorders to reach cures through advanced cell therapy. We work with a sense of urgency and deeply held responsibility to address the clear need for new treatment options. And we believe that cell therapies should be available to patients who can benefit from them.

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Gynica is a femtech company leading in the clinical development of cannabinoid-based therapeutic solutions to treat gynecological conditions and improve women's quality of life. We aim to provide evidence-based products that use an innovative local approach to effectively address undertreated gynecological conditions, such as painful menstruation and painful sexual intercourse, with no side effects. Why? 1. Women's health is experiencing a tidal wave of innovation, as both patients and physicians are looking for solutions that will specifically address women's health, tailor-made to women's biology. 2. Second only to the brain, the female reproductive system has the highest percentage of Anandamide endocannabinoid receptors, creating a potential special effect on women's health. We have made it our mission to develop new formulations, drug delivery methods, and technologies that will focus on utilizing this connection to provide effective medical products to women. As of today, we are the only company in Israel licensed to research the connection between cannabis and women's health. Gynica is led by world-renowned opinion leaders in gynecology, cannabinoids, and pharmacology. Our Board of Directors is Chaired by Prof. Moshe Hod, a leading expert in the field of women's health and the President of the European Association of Perinatal Medicine (EAPM). Our Scientific Committee is led by award-winner Prof. Lumir Ondrej Hanuš – the one behind the ground-breaking discovery of the endocannabinoid system, paving the way for decades of research into medical cannabis use. Gynica was founded in 2017 and our HQ is in Tel Aviv.

Healium Medical is focused on advancing atrial fibrillation treatment with an innovative no-contact guided ablation technology allowing simultenuous tissue ablation and lesion monitoring. The company operates out of Alon Medtech Ventures (http://www.alon-medtech.com) in Yokneam, Israel, and have demonstrated its proof-of-concept in an animal model. EP Physicians interested to collaborate, contibute to product defintnion and experience the technology first-hand are welcome to contact us.

HT BioImaging is a medical imaging company based in Tel Aviv, Israel, founded in 2015. The company specializes in innovative imaging technologies aimed at early cancer detection. Its main product is a patented medical imaging platform that uses Heat Diffusion Imaging (HDI) technology to create real-time images from heat diffusion in tissues. This platform is designed for immediate cancer detection at the point of care and in operating rooms. In addition to its primary focus on human healthcare, HT BioImaging has a subsidiary called HTVet, which applies its technology to the veterinary market. HTVet offers HT Vista, a non-invasive medical device that helps veterinarians rule out cancer in pets during clinical visits. The company serves hospitals and clinics, particularly in oncology and surgery, and is supported by a team of experts in various fields, including AI and thermodynamics.

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

ImmunoBrain Checkpoint (IBC) is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. IBC’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. IBC's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.

ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy for the treatment of solid tumors. The company is headquartered in Israel, with presence in Luxembourg, France and USA, as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel. ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.

InnoCan Pharma is a pharmaceutical company specializing in developing novel therapeutics that harness the unique healing properties of Cannabinoids to improve quality of life. OUR ADVANTAGES Led by a highly-experienced team with a proven track record of success, InnoCan will leverage Israel’s worldleading medical cannabis research community to develop powerful, Cannabinoid-combined, patent-pending formulas. Our outstanding products will be clinically validated by undertaking Post Marketing Surveillance (PMS) studies and combine smart delivery systems to enhance the potency and efficacy of current products for better results. EXPECTED EARLY REVENUES: InnoCan expects to generate early revenues ($30 million in 5 years) from the multi-billion dollar Over The Counter (OTC) market by leveraging the rapid FDA OTC drug monograph process or similar regulatory pathways in Europe and Canada. These regulatory pathways enable InnoCan, in a very short time, to bring to market outstanding new products that combine the huge therapeutic potential of Cannabinoid complex/hemp oil added “excipients” to existing approved OTC drugs. TECHNOLOGY: POWERFUL, PATENT PENDING FORMULAS WITH SMART DELIVERY SYSTEMS InnoCan's products will be highly differentiated within the market through the powerful synergistic effect of the Cannabis-complex Hemp Oil with the active ingredients, combined with our on-demand release delivery system providing improved patient efficacy and compliance. FIRST-LINE PRODUCTS: A LEAP-FORWARD IN DERMATOLOGY TREATMENT DESIGN The companies first products will initially target the multi-billion dollars markets of psoriasis and localized pain , where research shows topical cannabinoid-combined treatments are highly effective, followed by oral hygiene, eczema/ itching, skin support after chemotherapy and women's health. To join the investment opportunity with InnoCan, please contact Iris Bincovich at IrisB@InnocanPharma.com.

INSIGHTEC Ltd. is a global healthcare company that specializes in creating the next generation of patient care by harnessing the therapeutic power of acoustic energy. The company was founded in 1999 by GE Healthcare and Elbit Medical Imaging to bring MRI-guided focused ultrasound technology to the market. INSIGHTEC's technology uses sound waves to precisely target and ablate tissue with no incisions, minimal risk of infection, and often allows patients to undergo treatment on an outpatient basis.

INTEC PHARMA is a pharmaceutical distribution company that specializes in cold chain logistics for healthcare products.

Interna Therapeutics is an innovative biotechnology company that developed a transformational delivery technology for macromolecules. The pioneering technology, named Molecular Nano-Motors (MNMs), is based on a novel mechanism that leverages membrane electrical forces, facilitating entry of charged molecules into cells. With this technology new treatment options become available for a wide range of diseases using difficult to deliver molecules such as oligonucleotide-based drugs (siRNA, ASO). Equipped with full-capacity research facilities and working with leading research organizations, the team of seasoned scientists has demonstrated the therapeutic potential of MNM technology in numerous preclinical studies, with a Phase I study of a COVID-19 drug that began in September 2024. Interna's innovative spirit and scientific excellence has been recognized by key opinion leaders in the pharma industry and by non-governmental organizations.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

Isotopia is a global leader in innovative radiopharmaceuticals, driving advancements in medical diagnostics and therapeutic solutions. We specialize in developing, producing, and distributing radiopharmaceutical technologies that transform patient care and support medical research globally. Our Comprehensive Radiopharmaceutical Portfolio: Theranostics products: • Lu-177 chloride (non-carrier added and carrier added) Diagnostic and Imaging products: • Isoportrace®- PSMA-11 kit for Ga-68 labeling for prostate cancer imaging Nuclear Pharmacy products: • PET and SPECT products. Global Operations: 1. Israel: • HEADQUARTERS & LU-177 PRODUCTION SITE: Our global headquarters we are dedicated to the production of Lutetium-177 (Lu-177), a critical radionuclide for cancer therapies. This site ensures consistent quality and supply for our global customer base. • ASEPTIC PLANT & CMO SERVICES: Our aseptic plant in Israel specializes in the production of cold kits and offers comprehensive Contract Manufacturing Organization (CMO) services, including the manufacture of sterile and lyophilized products for clinical trials and commercial applications. 2. Austria: GMP-COMPLIANT LU-177 PRODUCTION: Our Austrian facility adheres to Good Manufacturing Practice (GMP) standards, ensuring high-quality production of Lu-177 for therapeutic use, particularly in cancer treatment. 3. United States: LU-177 ISOTOPIA PRODUCTION: Supporting North American operations, this site is focused on producing FDA-compliant Lu-177 Isotopia, meeting the needs of our customers across the region. Our Mission: Isotopia is dedicated to advancing medical breakthroughs with high-quality radiopharmaceuticals that enhance diagnostic accuracy and therapeutic outcomes worldwide. With over 160 professionals and 3 production sites, including 2 in Israel, we ensure a reliable, compliant supply of radiopharmaceuticals globally.

At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.

Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.

KAHR Medical is developing an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications

Kamada is a growing commercial-stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions. The company is a leader in the specialty plasma-derived field focused on diseases with limited treatment alternatives, with 6 FDA-approved products selling in over 30 countries. The company is advancing an innovative development pipeline targeting areas of significant unmet medical need.

Kamari Pharma was founded in 2018 to develop innovative treatments for unmet needs and rare diseases in dermatology. We are developing proprietary small molecules, selective TRPV3 inhibitors for regulation of skin physiology and pathology. We are aiming to treat conditions of the skin with no current treatments by targeting the root cause of Ca++ dysregulation. TRPV3 was established as a target for drug development and showed involvement in various skin disorders including Olmsted Syndrome, Keratodermas, Pruritus, Ichthyosis, Atopic Dermatitis, and others. The Company is comprised of individuals with vast experience in drug discovery and dermatology pharmaceutical development in the biotech industry, as well as clinical advisors who are world-class key opinion leaders in related scientific areas. Our team includes a strong board of directors with a proven track record of success in advancing therapies to treat both rare diseases and dermatologic diseases and conditions.

Limaca Medical Ltd, is a privately held company dedicated to improving endoscopic biopsy results for patients facing potentially life-threatening gastroenterology and pulmonary cancers. Limaca's experienced team of engineers, clinicians, and business professionals have track records of innovating, developing, and commercializing specialized medical devices. Limaca Medical was founded in 2017 in cooperation with Rambam Health Care, a leading Israeli medical center, and The Trendlines Group in collaboration with the Israel Innovation Authority.

Company Profile: LipoCure is start-up that focuses on development of nano-drugs based on liposomes. LipoCure utilizes the vast experience gained by Professor Yechezkel Barenholz, one of the major inventors and developers of the first FDA-approved nano-drug, Doxil®. Doxil is an anti-cancer drug considered as one of the gold standards of nano-drug delivery systems (DDS). The technological and biological knowledge gained during Doxil development has led to the development of anti-cancer nano-drugs with improved efficacy and reduced toxicity compared to Doxil, as well as to the development of anti-inflammatory nano-drugs. The LipoCure pipeline includes 3 projects close to clinical trials and other projects in pre-clinical stages. All the drugs developed by LipoCure share the principles of better control over pharmacokinetics and bio-distribution, passive targeting at the disease site and controlled drug release. All active pharmaceuticals used are generic. The overall superiority of LipoCure's novel drugs stems from the above advantages, enabling achieving an improved therapeutic index by improving efficacy and reducing toxicity. Technology Description: Utilizing the group's expertise in liposomes and nanotechnology, LipoCure has developed a pipeline of products: LC100 – Liposomal doxorubicin nano-drug with greater efficacy and reduced side effects, in particular, reduced hand and foot syndrome in comparison to current pegylated liposomal doxorubicin. LC200 – Long-circulating inflammation-targeted steroidal nano-liposomal drug with improved efficacy profile in pre-clinical animal models to be used as anti-inflammatory and anti-cancer drug. LC400 – ULALA (Ultra-Long-Acting Local Anesthetic) large multi-vesicular liposome hydrogel loaded with bupivacaine, with slow release and improved safety and efficacy demonstrated in first-in-human clinical study phase I.

LipoMedix is a biopharmaceutical company that develops drugs for cancer diseases.

Lumenis creates and commercializes innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. We have successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. Lumenis has a rich history of defying technological boundaries, redefining standards within our domains, and transforming people's lives - both inside and out. Our drive for innovation stems from an uncompromising commitment to providing best-in-class technologies and solutions designed to achieve excellent results. Lumenis has a solid global footprint in developed and emerging markets and sales in over 100 countries. Headquartered in Israel and with offices on four continents, our team consists of nearly 1,500 professionals worldwide.

Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.

Lydus Medical is a start-up company in the field of Microsurgery developing a novel system for automating the creation of a safe, simple and fast anastomosis. Vesseal™ is an automated microvascular suturing device delivering thread only standardized omni-vessel anastomoses, to enable simple, fast, easy, safe and effective procedures.

Magenta is developing miniaturized catheter-mounted axial flow-pumps for mechanical circulatory support indications, based on Magenta's core technology of self-expanding impellers and pump heads. Our percutaneous Left Ventricular Assist Device (pLVAD) is a next-generation low-profile arterial pump, intended for temporary support of patients undergoing high-risk coronary interventions and the treatment of patients admitted with cardiogenic shock.

Mapi Pharma is a late clinical stage pharmaceutical company, currently in the final stage of the Phase III with its lead product, GA Depot, a long-acting depot glatiramer acetate for treating MS and has several generic commercialized products. Mapi is engaged in the development of high barrier-to-entry and high added-value life cycle management products that target large markets and high barrier patented generic drugs that include complex API and formulations. The GA Depot injection, administered once every four weeks, is the first in a series of depot long-acting injections in the company's pipeline. The product is a long-acting version of Copaxone®. Mapi partnered with Mylan/Viatris Inc. (NASDAQ: VTRS) for GA Depot in an agreement under which Mylan was granted an exclusive license to commercialize the GA Depot injection product for relapsing forms of multiple sclerosis. Mapi is also in the midst of a Phase II with GA Depot for PPMS and has a pipeline of long acting depot including GLP-1 for treating diabetes and Parkinson's disease for which we are looking for strategic partners. Mapi is built on strong chemical and pharmaceutical R&D capabilities focused on long acting depot technologies and combination treatments including loaded exosomes derived from adipose tissue. Mapi is headquartered in Israel, with R&D facilities in Israel, an API production facility in the Neot-Hovav Eco Industrial Park and an aseptic manufacturing and a large scale Fill & Finish facility for injectable Finished Dosage Forms in Jerusalem totaling 45,000 ft2. Mapi Pharma was founded by Ehud Marom who serves as Chairman & CEO of Mapi Pharma and Stem Cell Medicine.

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.

An internationally-recognized and multi-disciplinary applied research institute, MIGAL specializes in biotechnology and computational sciences, plant science, precision agriculture and environmental sciences as well as food, nutrition and health.

Minovia Therapeutics is a clinical-stage international biotechnology company, established in hopes to bring life changing therapies to patients with Mitochondrial diseases, as fast as responsible. Following compassionate use cases performed in Sheba Medical hospital in Israel, using our proprietary Mitochondrial Augmentation Therapy, Minovia is now conducting the first of its kind clinical trial for Pearson syndrome, an ultra-rare pediatric disease.

MNDL Bio is a Synthetic Biology startup aiming to reduce cost and production time of food and biotech applications through advanced computational platforms that optimize gene expression. Proud winner of the "Coller Startup Competition" for Edition 2023.

Momentis Surgical (formerly Memic Innovative Surgery) is a medical device company founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary based in Fort Lauderdale, Florida. Momentis is dedicated to transforming the field of robotic surgery by developing innovative small footprint, cost-effective, robotic-assisted technologies and techniques for a growing number of clinical applications. Our goal is to empower surgeons to perform minimally invasive, complex procedures, enabling better patient outcomes, lowering cost of care, and opening access to more surgeons, patients, hospitals, and surgery centers across the globe. Community Guidelines: https://www.momentissurgical.com/social-media-guidelines/

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging

Nasus pharma develops Powder-Based Intranasal (PBI) specialized product portfolio to address acute medical conditions & public health threats.

Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents. Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.

NeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.

Neurim Pharmaceuticals is a neuroscience drug discovery and development company creating drugs for brain restoration & reinforcement, focusing on the central nervous system. With a proven track record of drug development and commercialization, Neurim’s first products, Circadin® and Slenyto® , are already in use in more than 40 countries across 5 continents. Constantly expanding into additional therapeutic areas, the R&D pipeline comprises new products that address insomnia, Alzheimer’s dementia and sleep apnea.

NeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration. By developing next-generation drug-device combination solutions for central nervous system disorders, we aspire to make a meaningful difference in patients’ lives and drive future healthcare connectivity. Our mission is to address the challenges of the future healthcare and wellbeing ecosystem. We are passionately driven to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies.

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Neuromagen Pharma is an early-stage pharmaceutical company developing a new class of innovative small molecules which activate telomerase reverse transcriptase (TERT) – an enzyme which plays a major role in aging-related diseases and in cellular senescence. Neuromagen's pipeline includes drugs for neurodegenerative diseases such as ALS and Alzheimer's, type 1 diabetes, fertility, and cardiovascular diseases.

Neurotrigger develops the next generation wearable powered muscle re-education stimulation system. Re-educating muscles is important for facilitating and improving muscle performance and muscle's range of motion, and for the prevention or retardation of disuse atrophy.

NewStem is a biopharmaceutical company focused on Human Pluripotent Stem Cells (HPSCs) in general and Human Haploid Pluripotent Stem Cells (HHPSCs) in particular. These cells have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research. NewStem possesses pioneering intellectual property, reagents and experience related to the isolation and differentiation of HPSCs, their genetic manipulation, immunogenicity, tumorigenicity and their unique capacity in disease modeling. With this innovative research, and specialized drug and gene screening capabilities. NewStem is currently the only company worldwide to develop products based on this paradigm changing proprietary tech-nology, licensed from Yissum, Hebrew University’s technology transfer company, based on the findings and in-ventions of Prof. Nissim Benvenisty, of the Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem.

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company's non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals while evaluating additional tests for other high-risk diseases.

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

OCON Therapeutics develops innovative and safe intra-uterine medical solutions that are inspired by women’s bodies and anatomy, to better the lives of women everywhere. In the past decade we have developed the IUB™ platform, our proprietary intrauterine ball-shaped technology, utilising super-elastic alloy Nitinol to carry long lasting hormone-free contraception and other drugs. OCON’s first product, the IUB™ Ballerine®, is a CE approved copper-based hormone-free intrauterine contraceptive, effective for up to 5 years, and already in use by over 100,000 women in 24 countries, including EU member countries, South Africa and Israel. The Company is currently enlisting patients for its phase II clinical trials with the IUB™ SEAD, a disposable, point of care therapy for the treatment of abnormal uterine bleeding (AUB), affecting 25% of women in the reproductive age. The SEAD (Spherical Endometrial Ablation Device) is designed to be a pain-free, non-invasive and cost-effective alternative for aggressive, invasive, painful and costly ablation procedures hundreds of thousands of women currently endure. In addition, we are working on a strong pipeline of more IUB™ based drug products, using the frame for myomas and other uterine indications. OCON’s technology platform and products are protected by a broad portfolio of patents and trademarks.

Olive Diagnostics is a health technology startup founded in 2019 and based in Jerusalem, Israel. The company focuses on developing innovative, non-invasive health monitoring technologies aimed at empowering individuals with continuous insights into their health data. This approach supports healthier lifestyles and improved healthcare outcomes. The company specializes in digital diagnostics, particularly with its non-invasive urinalysis sensor, the Olive KG. This device mounts to any toilet and utilizes optics, IoT technology, AI, and data analysis to provide real-time health alerts and disease detection. It is designed for early disease detection and chronic disease management by continuously collecting and analyzing health data, offering users historical insights and proactive health tips. Olive Diagnostics has a multidisciplinary team with expertise in various fields, including biochemistry and data analytics. The company is in the final stages of research and development and plans to launch its product by the end of 2024, positioning itself for growth in the digital diagnostics market.

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

OPKO Biologics Ltd. (formerly Prolor Biotech), a subsidiary of OPKO Health Inc., is a clinical stage company developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs, utilizing CTP and reversible PEGylation technologies. The CTP technology involves fusing one or more copies of a naturally occurring glycosylated peptide by rDNA technology to the protein chain ends. When attached to a therapeutic protein, CTP significantly extends its longevity in the body. OPKO Biologics’ second technology is reversible PEGylation, a synthetic chemistry-based platform for enhancing the half-life of therapeutic peptides and small molecules. Using a hydrolysable linker bypasses the disadvantages of using a standard PEGylated molecule, i.e. the potential for steric hindrance that limits its function, and the limited ability to cross cellular membranes or the blood-brain barrier. OPKO Biologics currently presents two bio-better long-acting products: hGH-CTP (Somatrogon, MOD-4023): CTP-modified human growth hormone (hGH). OPKO completed a pivotal Phase 3 study in growth hormone-deficient (GHD) adults and is currently conducting a Phase 3 study in a GHD pediatric population. The company completed a Phase 2 study in GHD adults, demonstrating that a single weekly injection of hGH-CTP could potentially substitute seven consecutive daily injections of regular hGH, and showing an excellent safety profile. OPK88005: CTP-modified long-acting coagulation factor VIIa, potentiality supporting every-other-day prophylactic treatment or twice a week regimen in hemophilia patients. OPK88005 is currently evaluated in an ongoing Phase 2a clinical study.

Oxitone is a leading wearables and digital health company helping providers deliver continuous remote care for people with severe chronic and complex conditions and ensure the best clinical outcomes. MAXIMIZE VALUE AT LOW COST The top 5% of people with severe chronic conditions account for 50% of care spending. Practicing fragmented care doesn't deliver help in time. Oxitone generates continuous remote measurements of multiple physiological parameters and their derivatives, so any critical deviations could be flagged and notified in a timely manner. Oxitone continuous monitoring solution helps to maximize care for patients while significantly reduce cost. VitalsTone™ AI-POWERED ANALYTICS ENGINE At the core of Oxitone is the VitalsTone™ exceptionally accurate personalized data analytics engine integrated with the #1 in the market FDA/CE certified wrist medical monitor Oxitone 1000M. It passively collects and analyses multiple critical physiological parameters and their derivatives (hospital-grade) in real time and guides personalized therapeutic decision-making ULNAR BONE FlexSense™ CONTINUOUS MONITORING TECHNOLOGY Oxitone 1000M is the first FDA-cleared wrist medical monitor that works without a bulky fingertip probe. Oxitone's elastics sensors gently embrace wrist ulnar bone, do not affect local blood flow and provide superior accuracy, comfort and monitoring continuity. The technology was intensively validated through FDA clearance and numerous clinical applications. Oxitone is spotlighted on The New York Times, MobiHealthNews, MedCityNews, and Digital Health Global 100. Won awards from Cleveland Clinic, NODE.Health, Tech Tour, and Hello Tomorrow. Oxitone was a part of StartUp Health and TEDMED Hive 2014.

PainReform Ltd. is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Their first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. The company is also involved in investor relations, stock performance, and earnings.

Panaxia is a pharmaceutical company specializing in medical cannabis R&D and manufacturing. We are bringing scientific rigor and pharmaceutical manufacturing standards to the rapidly evolving field of medical cannabis. As a leader in this category, Panaxia is spearheading the adoption of cannabis-based treatments by developing consistent, effective, high-quality products that can be taken through a variety of familiar delivery methods to substantially improve the lives of people with a wide range of medical conditions. We offer over 65 different products, all manufactured under extremely stringent Good Manufacturing Practice (GMP) guidelines and with the most advanced analytical and validation methods to meet the most demanding requirements for consistency and dosage accuracy. Panaxia is part of a group of leading Israeli pharmaceutical companies with more than four decades of experience and proven success. We invest substantially in research and development and have clinical partnerships with prominent medical centers. Operating around the globe, our network is extensive and ever growing. Collaborating with the world's best medical cannabis companies and organizations enables us to bring cannabis products of the highest quality and consistency to as many people as possible.

Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company. Pepticom's disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being. Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.

Pharma Two B is a clinical-stage pharmaceutical company developing novel, synergistic, combination products based on previously approved drugs. We refined our years of expertise to identify and characterize potential drug combinations that can offer high therapeutic effects with improved safety profiles. Our goal is to develop clinically meaningful and safe added-value combination products to address unmet medical needs. Our lead investigational product, P2B001, successfully completed both Phase IIb and Phase III studies for the treatment for early Parkinson’s Disease (PD).

Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCut™ is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.

We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes. Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer. Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden. We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems.

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.

Premia Spine is a medical technology company based in Netanya, Israel, founded in March 2011 by Ron Sacher. The company specializes in developing innovative spinal implants aimed at improving patient outcomes. Premia Spine focuses on providing alternatives to traditional spinal fusion surgeries through minimally invasive procedures that help preserve spinal flexibility and reduce pain. The company offers a range of spinal implant systems, including the TOPS™ System, which treats spinal stenosis and spondylolisthesis while allowing for natural motion and providing pain relief. Other products include the ProMIS™ System and Nexux™ Systems, designed for treating back and leg pain through minimally invasive techniques. Premia Spine also provides training and clinical support for healthcare providers to ensure effective integration of its products into treatment protocols. With a commitment to advancing spinal care, Premia Spine has filed 20 patents and raised $7 million in funding, focusing on orthopedic and neurosurgical innovations.

Prodalim Group provides optimized solutions to bottling companies across the globe. More simply put, we do all of the hard work to get top-quality fruit juices into the hands of bottling companies, who then make sure that those same juices fill your glass. To make this happen, we start by understanding the specific needs of our customers. We proceed to carefully research the flavors consumers will like the most, meticulously choose top quality growers from whom to buy fruit, figure out the best, and most eco-friendly way to press, blend and store the juices we produce, and finally, how to effectively and efficiently transport our products to our customers, premium bottlers across the world. What's our Secret? We hold as our operational cornerstones 4 central principles that are the basis for our market beating results: Innovation Integrity and Reliability Quality Partnership and Fairness These values come to bear in the 360° solutions we offer to our customers including product research and development, sourcing of raw materials, manufacturing, blending, compounds, storing, and distribution. From our various offices and distribution centers; NL, Spain, Italy, Brazil and China, using a network of growers in 35 countries, we've constructed a wide portfolio of raw material related to the juice and citrus oils industry product offerings and organized multiple distribution centers, allowing us to be substantially more responsive and competitive to our customers. Our 350customers in over 50 countries, including some of the world's top, blue-chip bottlers are well aware of this commitment to excellence and to them. They, in turn, repay us in trust, loyalty, cooperation and close to 30 years of collaboration, and, of course, in a growing base of business activity. Prodalim brings the best solutions, in terms of product quality, efficiency, customer service and cost, to bottling companies in all corners of the planet.

Utilizing a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data

Pronto Diagnostics is a leading provider of molecular diagnostic products and services, with extensive knowledge, experience and R&D capabilities in genetic analysis. ProntoLab™, Pronto's molecular services laboratory, has accreditation from the Israel Ministry of Health and ISO 9001:2008 certification. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes. Pronto Diagnostics has been granted exclusive distribution rights in Israel from leading international molecular diagnostic companies to high quality products and technologies. We are cooperating with the best and most advanced labs in the world such as Centogene, TheragenEtex, Sequenom, MRC-Holland, 10x Genomics, Multiplicom-Agilent, Sophia genetics, DNA Genotek and many more. Pronto Diagnostics provides highly professional technical support. Its product specialists are dedicated to supporting the company's customers wherever they may be. For more details please contact our office at : info@prontodiagnostics.com

ProSpec (Protein-Specialists) is a leading biotechnology company having over 20 years of experience specializing in production of prokaryotic and eukaryotic-derived recombinant proteins. The company provides highly purified proteins worldwide which serve the life science research community with cytokine-related products. Our goal is supplying many recombinant proteins which serve the academic and R&D industry. We have been able to assemble more than 7000 recombinant proteins, peptides and antibodies which are crucial to the research community.

Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

Protalix (NYSE American, TASE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX 110, for the treatment of various human respiratory diseases or conditions; PRX 115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX 119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240. *NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. *CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. *IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong, localized immune response within the tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA) 5T4 that is expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. IM1240 has a cleavable capping technology that confines the compound’s therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients.

When treating stroke, procedural time and patient safety are critical. Utilizing advanced technology backed by clinical data, Rapid Medical expands what's possible in neurovascular treatment by offering interventional devices that are fully visible and adjustable in the brain. The result? The unique ability to tailor the procedure to every patient.

RCK is an Israeli cannabis company, breeding repeatable & stable cannabis hybrid-seeds, for both medical & recreational markets.

Here at Redefine Meat, we believe the world deserves better meat – a new kind of meat that's good for the environment, kinder to animals, and of course, delicious. With cutting-edge technology, we've created plant-based ‘New Meat' that has the same flavor, texture, and versatility as animal meat. We offer a wide range of products suitable for any type of cuisine and cooking style.

Our mission at Restore Medical is to provide a unique solution for patients with congestive heart failure (CHF). CHF is one of the leading causes of death and hospitalization, affecting millions worldwide. Patients remain with disabling symptoms despite receiving currently-available optimized medical treatment. To that end, we have developed ContraBand™, a novel catheter-delivered implant which aims to improve CHF patients’ quality-of-life and reduce hospital readmission rates.

Salignostics is an R&D company focusing on the development of saliva based rapid diagnostics tests (RDT), utilizing a lateral flow immunoassay platform. The company's platform is comprised of a "tool box"​ of technologies which amplify the saliva as a detectable body-fluid by overcoming different chemical and biological saliva related obstacles. Implementation of these technologies transforms saliva from a non-detectable to a detectable body-fluid

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products. Previously known as BiondVax Pharmaceuticals, the company has undergone significant changes, including a shift in focus and a rebranding to reflect a new strategic direction. Scinai Immunotherapeutics is also working on an innovative plaque psoriasis treatment that has shown encouraging preclinical results.

SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.

Senseera's GEM (Genomic Expression Maps) BIOMARKERS, is a novel biomarker discovery platform based on a patent protected chromatin epigenomics (cfChIP-seq) liquid biopsy technology (Sadeh, Nature Biotechnology, 2021). GEM BIOMARKERS turns a simple blood draw into unparalleled, quantitative, cell-specific gene expression, and regulation data from cell-free DNA. Going beyond traditional methods like cfDNA genomics and methylation, it offers a transformative layer of data for various applications including biomarker discovery, tissue-agnostic MRD detection, response to therapy, dose optimization, disease subtyping and more. Backed by a database of over 20,000 annotated disease samples and a 2,000+ healthy subjects cohort, Senseera is collaborating with leading drug developers from big pharma and biotechs, to deliver mechanistic insights with exceptional sensitivity and specificity across multiple indications, advancing human health and precision medicine worldwide.

Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The company's platform technology is addressing difficult-to-treat solid tumors. Silexion's lead product candidate, SIL-204, consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy. SIL-204 is a siRNA product candidate following Phase 1 and Phase 2 clinical trials with Silexion's first-generation siG12D-LODER, also referred to as LODER™. Results from the LODER™ Phase 2 clinical trial showed a trend for differences between treatment groups with the LODER arm suggesting an overall survival advantage of 9.3 months. Silexion commitment to Pushing the boundaries of therapeutic advancements in the field of oncology is focused on its second-generation microparticle delivery system, SIL-204 a newly formulated product that will improve clinical efficacy. Silexion plans to conduct a Phase 2/3 trial of SIL-204 in locally advanced pancreatic cancer patients that harbor the KRAS G12D and G12V mutations. Silexion Therapeutics Ltd. is headquartered in Israel and partnered with well known GMP compliant siRNA facility, LGC Axolabs group located in Petaluma California, and worldwide experts extended-release formulation facility, EVONIK Corporation located in Birmingham, Alabama to upscale manufacturing.

SKIP Therapeutics develops RNA-based therapies for rare genetic disorders and common diseases – utilizing a proprietary computational discovery engine to optimize target selection and therapeutic design. We employ sequence-based molecules, called Antisense Oligonucleotides (ASO), to restore function of mutated genes in rare genetic disorders or to modify functionality of key genes in major disease pathways. Convergence of SKIP’s novel computational discovery engine alongside strong experimental capabilities form a unique venture in the landscape of RNA-based therapies. Thousands of rare genetic disorders affect millions of people worldwide, however the small number of patients for each disease, further segregated by patient-specific mutations, has hindered development of dedicated treatments. Recent advancements in RNA-therapeutics offer an expanded molecular toolkit that can be deployed rapidly and at low costs to restore protein function of mutated genes. Identifying sub patient-populations that could potentially be suitable for treatment with RNA-based therapeutics and matching molecular treatment-strategies across the vast landscape of known disease-causing mutations could be assisted by computational methods. To facilitate development of dedicated treatments, Skip Therapeutics has developed a bioinformatic pipeline that analyzes disease-causing mutations and recognizes the best molecular strategy (if any) to restore protein function, using splice modulating antisense oligonucleotides (ASOs). Analyzing mutation data at scale, enables identification of treatable patient cohorts and optimizes target selection. Top candidates from the computational analyses are experimentally validated and pursued for therapeutic development.

Sol-Gel Technologies (NASDAQ: SLGL) is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our unique technology platform was designed to enable drug substances to be entrapped in porous silica microcapsules in order to address the limitations of topical drug delivery by stabilizing active drug ingredients, extending drug delivery time and reducing potential irritation caused by direct application to the skin.

SpliSense Ltd., is a growing and exciting biotechnology company, developing novel therapies for genetic diseases by inhalation. The company is currently focusing on splicing mutations in the CFTR gene for treating Cystic Fibrosis (CF) patients.

STERO, founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy. STERO's extremely wide coverage patent (CBD from any source, in any combination, any dosage, in any delivery system, all for more than 130 diseases by name) was Issued in the US on August 2018 and is pending in main countries around the world. Stero currently has 3 ongoing clinical trials, 2 phase 2a clinical trials in Crohn's disease, and in Chronic Urticaria (Hives), 1 phase 1/2 clinical trial treating severe covid-19 patients, all covered by Stero's IP & pursuing the FDA drug route, with more in the pipeline.

SuperMeat is a Tel Aviv-based food tech company working to supply the world with high quality meat grown directly from animal cells. At SuperMeat, food technologists, engineers, biologists, and chefs work together to craft the world's greatest meat products, manufactured in a sustainable and animal-friendly way.

TargetGene is an innovative and agile biotechnology company in it’s development stage poised for expansion. TargetGene’s R&D is centered around creating efficient and supremely specific DNA editing solutions in living organisms. TargetGene, with it's patented and patent pending "T∙GEE"​ (Genome Editing Engine) platform is the first to invent RNA-guided gene-targeting. TargetGene is aiming to implement the "T∙GEE"​ platform for human gene-therapy with a focus on inherited diseases and cell-based immunotherapy. TargetGene’s platforms include In-Vivo assembling nucleases targeted to the cell's genetic material. Highly specific Targeting is achieved through use of the principle of nucleic acid hybridization. Keywords: Genome editing, Gene Targeting, Genome engineering, Nucleases, RNA-guided Genome Engineering (RGEN), Immunotherapy, Cell-based Therapy, Gene Thearapy, Immuno-oncology. Our new laboratories are situated in the Rehovot Science park, Oppenheimer 10, Rehovot, Israel.

Tarsier® Pharma is a clinical late stage company developing novel treatments for ocular inflammatory blinding diseases, beginning with uveitis.

TechnoPulm introduces a disruptive diagnostic tool for Pulmonary-Function Testing (PFT) in patients suffering from respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, covid related ailments and others. TechnoPulm is the only company that has systems that allows ALL lung function diagnostic tests to be performed from the doctor's office and the patient's home by using a small handheld device connected to a comprehensive tool to enable a remote healthcare solution. TechnoPulm enables patients to interact with their physician from anywhere at any time.

Ukko is improving the lives of millions that suffer from food allergies and disorders. We are using cutting edge technologies in immunology, computational biology, and plant science to develop a new approach. We have offices in Tel Aviv, Israel and Palo Alto, California.

Vascular Graft Solutions (VGS), was founded in 2009 and is focusing on the development and commercialization of innovative solutions to improve the outcome of bypass surgeries. The company's leading product, the VEST (Venous External Scaffolding Technology), is a novel external mechanical support for autologous vein grafts, intended for improving vein graft longevity. Pre-clinical and clinical studies confirmed that by restraining wall tension and improving lumen uniformity, the VEST optimizes vein graft hemodynamics and mitigates vein graft disease. Randomized controlled trials and real-world data studies in Europe, demonstrated the biomechanical effect of external stenting, its statistically significant mitigation of vein graft disease, and improved clinical outcomes.

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.

Vensica Medical is a medical device company that is designing and developing and Ultrasound catheter for the treatment of bladder cancer. Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica's device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.

Vessi Medical is developing an innovative, IP protected cryo spray for hollow & humid organs, a new approach in the treatment of Non Muscle Invasive Bladder Cancer.

Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncology and dermatology ailments. We at Vidac are passionate about transforming breakthrough science into innovative therapies to address major unmet medical needs. Our breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, thus holds the promise of delivering first-in-class drugs that are both efficacious and well tolerated by patients.

V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave's vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company's senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.